NCT04436068

Brief Summary

Participants with known or suspected hydrocephalus will receive brain scans using the Hyperfine, low field strength, portable, magnetic resonance imaging (MRI) system in addition to their scheduled outpatient standard of care clinical computed tomography (CT) or MRI scan. The purpose of this pilot study is to evaluate the feasibility and acceptability of using the Hyperfine system in an outpatient setting and to compare its diagnostic performance to standard clinical imaging. Outpatients with other known or suspected neurological disorders or conditions prompting routine clinical brain imaging with MRI or CT will also be enrolled and the diagnostic performance of low field scans compared to that of the same day standard of care clinical imaging.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started Jun 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Jun 2019Jan 2027

Study Start

First participant enrolled

June 28, 2019

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

June 10, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 17, 2020

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2027

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Last Updated

May 5, 2026

Status Verified

May 1, 2025

Enrollment Period

7.6 years

First QC Date

June 10, 2020

Last Update Submit

April 29, 2026

Conditions

Keywords

MRIMagnetic Resonance ImagingCTShunt

Outcome Measures

Primary Outcomes (3)

  • Presence of hydrocephalus

    Presence or absence of hydrocephalus will be determined qualitatively based on neuroradiologist interpretation of low-field MRI scans and companion standard clinical MRI or CT scans to evaluate performance using the low-field device to make this determination.

    Through study completion, an average of 60 minutes

  • Quantitative ventricular volumes

    Quantitative ventricular volumes (mL) will be obtained and compared for low-field and companion standard clinical MRI scans.

    Through study completion, an average of 60 minutes

  • Presence of other important imaging findings

    Presence of other important imaging findings will be determined qualitatively based on neuroradiologist interpretation of low-field MRI scans and companion standard clinical MRI or CT scans.

    Through study completion, an average of 60 minutes

Study Arms (2)

Outpatients with known or suspected hydrocephalus

EXPERIMENTAL
Device: Hyperfine MRI scan

Outpatients with other known or suspected neurological condition

EXPERIMENTAL
Device: Hyperfine MRI scan

Interventions

Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.

Outpatients with known or suspected hydrocephalusOutpatients with other known or suspected neurological condition

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older
  • Suspected or confirmed diagnosis of hydrocephalus from Penn referring physician
  • Other suspected or confirmed neurological disorder from Penn referring physician
  • Routine clinical CT or MRI of the brain scheduled/obtained on the same day as Hyperfine imaging.
  • Informed consent obtained from patient or legally authorized representative

You may not qualify if:

  • Contraindications to routine 1.5T MRI evaluation, including electrical implants such as cardiac pacemakers or perfusion pumps, ferromagnetic implants such as aneurysm clips, surgical clips, protheses, artificial hearts or heart valves with steel parts, metal fragments, shrapnel, tattoos near the eye, steel implants, or other irremovable ferromagnetic objects
  • History of uncontrolled seizures
  • Claustrophobia
  • Weight greater than or equal to 400lbs (181.4kg)
  • Pregnancy
  • Inability or suspected inability to comply with the study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

HydrocephalusNervous System Diseases

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Radiology

Study Record Dates

First Submitted

June 10, 2020

First Posted

June 17, 2020

Study Start

June 28, 2019

Primary Completion (Estimated)

January 30, 2027

Study Completion (Estimated)

January 31, 2027

Last Updated

May 5, 2026

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations